Skip to content
Screener

Interest Expense at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$93M-27.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$2.78M-6.9%
HRO
HarrowHROW
$5.5M-16.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$11M+206%
Journey Medical Corporation logo
Journey Medical CorporationDERM
$892K+0.1%
PTH
Pelthos TherapeuticsPTHS
$2.35M+1,656%

Segments

By segment

See full
Reportable Segment$2.16M-3.8%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations before other income (expense)(19,908)(22,184)(26,030)(48,464)
Other income (expense):
Interest income3,6984,2297,4207,683
Interest expense(2,156)(2,240)(4,284)(4,453)
Gain on exchange of long-term investments2,8122,812
Other income (expense), net(281)(145)(368)(226)
Total other income (expense), net4,0731,8445,5803,004
Provision for income taxes(2,716)(5,068)

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s interest expense?
Tarsus Pharmaceuticals, Inc. (TARS) reported interest expense of $2.16M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s interest expense changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s interest expense decreased by 3.8% year-over-year, from $2.24M to $2.16M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s interest expense?
Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s interest expense has grown at a 386.1% compound annual growth rate (CAGR), from $16K to $8.94M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude